Epigene Labs Company Profile

Background

Overview

Epigene Labs is a biotechnology company specializing in precision oncology research and drug development. Founded in 2019 by Akpéli Nordor and Arthur de Garidel-Thoron, the company operates dual headquarters in Paris, France, and Boston, USA. Its mission is to transform vast genomic data into actionable insights, accelerating the development of personalized cancer treatments.

Mission and Vision

Epigene Labs is committed to revolutionizing precision oncology by making complex genomic data accessible and actionable. The company aims to provide the biopharmaceutical industry with solutions that lead to more effective and personalized cancer therapies.

Key Strategic Focus

Core Objectives

Data Integration: Utilizing artificial intelligence to harmonize fragmented multi-omic datasets into structured, ready-to-use data for oncology research and development.

Accelerated Drug Discovery: Enhancing the speed and precision of oncology clinical trials through advanced data analysis and patient selection strategies.

Primary Markets

Epigene Labs targets the global biopharmaceutical sector, focusing on partnerships with leading cancer research institutes and pharmaceutical companies to advance precision oncology initiatives.

Financials and Funding

Funding History

Pre-Seed Funding (March 2019): Secured initial funding led by Daphni and Majycc Innovation Santé/UI Investissement.

Seed Funding (July 2020): Completed a seed funding round led by XAnge.

EIC Accelerator Grant (December 2021): Awarded a grant from the European Commission's EIC Accelerator program.

EIC Fund Investment (October 2023): Received financial backing from the European Innovation Council Fund.

Utilization of Capital

The funds have been allocated to:

Advancing the development of the mCUBE platform.

Expanding research and development capabilities.

Establishing strategic partnerships to enhance precision oncology research.

Technological Platform and Innovation

mCUBE Platform

Epigene Labs' proprietary mCUBE platform is designed to integrate and analyze multi-dimensional genomic data, facilitating:

Target Discovery: Identifying novel drug targets.

Biomarker Identification: Discovering biomarkers for patient stratification.

Patient Selection: Enhancing patient selection criteria for clinical trials.

The platform processes data from over 100,000 patient samples across more than 1,000 datasets, covering over 30 cancer types.

Proprietary Technologies

InMoose: An open-source Python package for multi-omic analyses, introduced in 2023.

pyComBat: A Python tool for batch effects correction in high-throughput molecular data, published in 2020.

Leadership Team

Akpéli Nordor: CEO & Co-founder. Holds a dual PharmD-PhD from Université Paris Cité and completed advanced research training at Harvard Medical School.

Camille Marijon: VP of Translational Research. PhD in Bioengineering and Biomaterials from Imperial College London.

Julien Haziza: VP of Product, Data & Technology. Holds a PharmD from Université Paris Descartes and MSc degrees from École CentraleSupélec and ESSEC Business School.

Abdelkader Behdenna: VP of Computational Research. PhD in Genetics and Bioinformatics from Université Pierre et Marie Curie.

Kevin Cho: VP of Business Development. BSc from the University of California, San Diego.

Vincent Hagenbourger: Lead People & Finance.

Competitor Profile

Market Insights and Dynamics

The precision oncology market is experiencing significant growth, driven by advancements in genomic research and personalized medicine. The integration of artificial intelligence in drug discovery is a key trend, enhancing the efficiency and accuracy of developing targeted therapies.

Competitor Analysis

Epigene Labs operates in a competitive landscape with several notable companies:

Mcule: Provides a drug discovery platform.

A-Alpha Bio: Develops a synthetic biology platform, AlphaSeq, for multi-target drug development.

Codexis: Specializes in protein engineering for pharmaceutical applications.

Great Bay Bio: Focuses on developing digital platforms for biopharmaceutical applications.

These competitors offer various platforms and technologies aimed at enhancing drug discovery and development processes.

Strategic Collaborations and Partnerships

Institut Curie

In April 2020, Epigene Labs partnered with Institut Curie to discover biomarkers and therapeutic targets for ovarian cancer, combining Institut Curie's oncology expertise with Epigene's data-driven technology.

Servier

In March 2025, Epigene Labs expanded its collaboration with Servier to advance AI-driven precision oncology research and development, utilizing the mCUBE platform to enhance clinical trial precision through patient selection and biomarker identification.

Operational Insights

Epigene Labs differentiates itself through its mCUBE platform, which integrates extensive multi-omic data to accelerate drug discovery and development. The company's strategic partnerships with leading research institutions and pharmaceutical companies enhance its market position and innovation capacity.

Strategic Opportunities and Future Directions

Epigene Labs is poised to expand its technological capabilities and market reach by:

Enhancing the mCUBE Platform: Continuing to develop and refine the platform to support a broader range of oncology research applications.

Forging New Partnerships: Establishing collaborations with additional biopharmaceutical companies and research institutions to further precision oncology initiatives.

Advancing AI Integration: Leveraging artificial intelligence to improve data analysis and interpretation, thereby accelerating the development of personalized cancer treatments.